FI945839A0 - Bentsotiofeeniyhdisteiden ja vesiliukoisten syklodekstriinien inkluusiokompleksien vesipitoinen liuos ja niiden farmaseuttiset formulaatiot sekä menetelmä - Google Patents

Bentsotiofeeniyhdisteiden ja vesiliukoisten syklodekstriinien inkluusiokompleksien vesipitoinen liuos ja niiden farmaseuttiset formulaatiot sekä menetelmä

Info

Publication number
FI945839A0
FI945839A0 FI945839A FI945839A FI945839A0 FI 945839 A0 FI945839 A0 FI 945839A0 FI 945839 A FI945839 A FI 945839A FI 945839 A FI945839 A FI 945839A FI 945839 A0 FI945839 A0 FI 945839A0
Authority
FI
Finland
Prior art keywords
methods
pharmaceutical compositions
inclusion complexes
water
aqueous solution
Prior art date
Application number
FI945839A
Other languages
English (en)
Swedish (sv)
Other versions
FI945839A (fi
Inventor
Henry Uhlman Bryant
George Joseph Cullinan
Paul Clifton Francis
David Edward Magee
Stephanie Ann Sweetana
Arvind Lavji Thakkar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945839A0 publication Critical patent/FI945839A0/fi
Publication of FI945839A publication Critical patent/FI945839A/fi

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI945839A 1993-12-14 1994-12-12 Bentsotiofeeniyhdisteiden ja vesiliukoisten syklodekstriinien inkluusiokompleksien vesipitoinen liuos ja niiden farmaseuttiset formulaatiot sekä menetelmä FI945839A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16678893A 1993-12-14 1993-12-14

Publications (2)

Publication Number Publication Date
FI945839A0 true FI945839A0 (fi) 1994-12-12
FI945839A FI945839A (fi) 1995-06-15

Family

ID=22604709

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945839A FI945839A (fi) 1993-12-14 1994-12-12 Bentsotiofeeniyhdisteiden ja vesiliukoisten syklodekstriinien inkluusiokompleksien vesipitoinen liuos ja niiden farmaseuttiset formulaatiot sekä menetelmä

Country Status (27)

Country Link
US (1) US5624940A (fi)
EP (1) EP0658348B1 (fi)
JP (1) JPH07196495A (fi)
KR (1) KR950017949A (fi)
CN (1) CN1109751A (fi)
AT (1) ATE205726T1 (fi)
AU (1) AU689817B2 (fi)
BR (1) BR9404936A (fi)
CA (1) CA2137533A1 (fi)
CO (1) CO4340621A1 (fi)
CZ (1) CZ306394A3 (fi)
DE (1) DE69428334T2 (fi)
DK (1) DK0658348T3 (fi)
ES (1) ES2160615T3 (fi)
FI (1) FI945839A (fi)
HU (1) HUT72298A (fi)
IL (1) IL111930A0 (fi)
NO (1) NO944764L (fi)
NZ (1) NZ270077A (fi)
PE (1) PE36795A1 (fi)
PH (1) PH31265A (fi)
PL (1) PL306173A1 (fi)
PT (1) PT658348E (fi)
RU (1) RU2135176C1 (fi)
SI (1) SI0658348T1 (fi)
YU (1) YU72594A (fi)
ZA (1) ZA949715B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US6180075B1 (en) 1997-04-09 2001-01-30 Degussa-H{umlaut over (u)}ls Aktiengesellschaft Exhaust gas catalyst
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US20030232068A1 (en) * 2002-06-14 2003-12-18 Lewandowski Daniel J. Food product having increased bile acid binding capacity
US20040157096A1 (en) * 2002-10-07 2004-08-12 Peterson Richard B. Plug-compatible modular thermal management packages
US20040116382A1 (en) * 2002-12-13 2004-06-17 Plank David W. Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
US7335386B2 (en) * 2003-07-30 2008-02-26 Gerneral Mills, Inc. Method for preventing acrylamide formation in food products and food intermediates
US20040180125A1 (en) * 2003-03-11 2004-09-16 Plank David W. Cyclodextrin-containing compositions and methods
EP2289488A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US20090318560A1 (en) * 2007-02-26 2009-12-24 Wayne Parent Formulations for cathepsin k inhibitors
EP2253627A1 (en) * 2009-05-21 2010-11-24 ERREGIERRE S.p.A. Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
CN102198274B (zh) * 2011-03-30 2013-04-24 天津红日药业股份有限公司 雷洛昔芬的环糊精包合物及其制剂的制备方法
ITMI20121821A1 (it) * 2012-10-25 2014-04-26 Erregierre Spa Composizione farmaceutica solubile in acqua a base di un sale di raloxifene

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
GB8814725D0 (en) * 1988-06-21 1988-07-27 Glaxo Group Ltd Medicaments
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
JPH02279631A (ja) * 1989-04-18 1990-11-15 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法
JPH02300140A (ja) * 1989-05-12 1990-12-12 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5101065A (en) * 1991-02-04 1992-03-31 Imperial Chemical Industries Plc Acetophenone intermediates
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
ZA949715B (en) 1996-06-06
RU94042935A (ru) 1997-01-10
AU8033594A (en) 1995-06-22
ES2160615T3 (es) 2001-11-16
RU2135176C1 (ru) 1999-08-27
DK0658348T3 (da) 2001-11-12
BR9404936A (pt) 1995-08-08
PL306173A1 (en) 1995-06-26
CO4340621A1 (es) 1996-07-30
EP0658348A3 (en) 1996-08-07
AU689817B2 (en) 1998-04-09
JPH07196495A (ja) 1995-08-01
DE69428334D1 (de) 2001-10-25
NO944764D0 (no) 1994-12-08
PE36795A1 (es) 1995-11-06
NZ270077A (en) 1996-04-26
YU72594A (sh) 1997-07-31
NO944764L (no) 1995-06-15
CZ306394A3 (en) 1995-08-16
PH31265A (en) 1998-06-18
EP0658348B1 (en) 2001-09-19
SI0658348T1 (en) 2002-06-30
ATE205726T1 (de) 2001-10-15
DE69428334T2 (de) 2002-06-20
IL111930A0 (en) 1995-03-15
PT658348E (pt) 2002-02-28
HU9403567D0 (en) 1995-02-28
FI945839A (fi) 1995-06-15
CA2137533A1 (en) 1995-06-15
CN1109751A (zh) 1995-10-11
KR950017949A (ko) 1995-07-22
US5624940A (en) 1997-04-29
EP0658348A2 (en) 1995-06-21
HUT72298A (en) 1996-04-29

Similar Documents

Publication Publication Date Title
FI945839A0 (fi) Bentsotiofeeniyhdisteiden ja vesiliukoisten syklodekstriinien inkluusiokompleksien vesipitoinen liuos ja niiden farmaseuttiset formulaatiot sekä menetelmä
FI941262A0 (fi) 3-aroyylibentso(b)tiofeenien sulfonaatti- ja karbamaattijohdannaisia
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
CR6540A (es) Trifluorobutenos nematicidas
EP0911039A3 (en) Drug-resin complexes stabilized by chelating agents
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
IT8219908A0 (it) Derivati di ferro biodisponibile esenti da gastrolesivita',procedimento di preparazione e relative composizioni farmaceutiche.
NO900612L (no) Preservativ for vandige sammensetninger.
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
FI101704B1 (fi) Menetelmä uusien, antiateroskleroottisina aineina käytettävien bis[4-(2,6-dialkyyli)fenoli]silaanijohdannaisten valmistamiseksi
MX9603602A (es) Anticuerpo especifico para fibrina para su uso como agente antitrombotico.
KR960013376A (ko) 철과 디프룩토오스를 함유하는 빈혈치료제
NO20002408L (no) 5-HT1F antagonister
IT8919735A0 (it) Procedimento per la riduzione del cod da reflui industriali o urbani.
FI902238A0 (fi) Synergistisk soetningskomposition och foerfarande foer des framstaellning.
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
ES2162203T3 (es) Procedimiento de preparacion de 3-piperazinilbenzoisotiazoles.
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
ES1019971Y (es) Pieza para juegos de composicion.